ArticleDiscover nano2026
Bimetallic nano mixtures enable rapid ultrasensitive detection of high risk HPV for early cervical cancer diagnosis.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-risk human papillomavirus (HPV) infection, particularly HPV16 and HPV18, is the primary etiological factor in cervical cancer development. The oncogenic potential of these viruses stems from the action of viral E6 and E7 oncoproteins, which drive malignant transformation by degrading tumor suppressor proteins p53 and pRb, disrupting cell cycle regulation, and inducing genomic instability [1, 2]. These mechanistic insights underscore the critical need for sensitive, rapid, and reliable diagnostic tools suitable for point-of-care settings to enable early detection and intervention.
methodsWe designed, synthesized, and evaluated bimetallic nano mixture-based lateral flow assays (LFAs) employing Au-Cu, Ag-Cu, and Ag-Au nano mixtures for detection of HPV16 L1 and HPV18 L1 capsid proteins. Nanoparticles were characterized by dynamic light scattering (DLS), zeta potential analysis, scanning electron microscopy (SEM), Fourier transform infrared (FTIR) spectroscopy, UV-Vis spectroscopy, and X-ray photoelectron spectroscopy (XPS) before and after functionalization with CTAB and monoclonal antibodies. Analytical performance including linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, precision, specificity, and stability was systematically validated. Clinical evaluation was conducted using 100 cervical samples, with performance parameters calculated against PCR as reference standard. Additional experiments were performed to assess early infection detection capability, correlation with E6/E7 oncoprotein expression, and specificity in the presence of p53 and pRb tumor suppressor proteins.
resultsPhysicochemical characterization revealed successful antibody conjugation across all formulations, with predictable increases in hydrodynamic size (5-7 nm) and shifts toward less negative zeta potentials (-30 to -35 mV). Among monometallic systems, Au nanoparticles demonstrated the highest analytical sensitivity (LOD = 1 ng/mL), while Cu nanoparticles showed the poorest performance (LOD = 12 ng/mL). Remarkably, bimetallic nano mixtures dramatically outperformed monometallic counterparts, with Ag-Au nano mixtures achieving the lowest LOD (0.15 ng/mL), highest linearity (R
conclusionBimetallic nano mixture-based LFAs, particularly the Ag-Au formulation, represent a highly sensitive, specific, and rapid point-of-care diagnostic platform for HPV detection. By enabling early identification of high-risk HPV infection-the critical initiating event in cervical carcinogenesis driven by E6/E7-mediated disruption of p53 and pRb tumor suppressor pathways-this platform addresses a crucial need in cervical cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.